Trigemino-autonome Cephalgien

Zusammenfassung

In der zweiten Fassung der Internationalen Kopfschmerzklassifikation der IHS wird erstmals die neue Gruppe der so genannten trigemino-autonomen Cephalgien (TAC) definiert. Es handelt sich dabei um relativ seltene, streng einseitige Kopfschmerzen mit periorbitalem Maximum und typischer autonomer Begleitsymptomatik. Welche Einteilungskriterien, Pathophysiologie und Behandlungsoptionen sich hinter dieser neuen Gruppenklassifikation verbergen und welche Intention bzw. Vorteile damit vergesellschaftet sind, stellt der vorliegende Übersichtsartikel vor.

Summary

The second edition of the International classification of headache disorders classifies for the first time the new group of trigeminal autonomic cephalalgias (TACs). These relatively rare headache syndromes are characterised by very intense periorbital pain with facial autonomic symptoms. The following article describes the symptomatic criteria, the pathophysiology as well as the therapeutic options of the new TAC classification and discusses the intention and advantages associated with this new group of primary headache syndromes.

Schlüsselwörter

TAC - Clusterkopfschmerz - SUNCT - paroxysmale Hemikranie

Keywords

TACs - cluster headache - SUNCT - paroxysmal hemicranie

• Literatur

• 1 Headache Classification Subcommittee of the IHS. The International Classification of Headache Disorders. 2nd edition. Cephalalgia. 2004. 24 Suppl 1: 9-160 Deutsche Übersetzung: Kopfschmerzklassifikationskomitee der International Headache Society. Die Internationale Klassifikation von Kopfschmerzerkrankungen; 2. Auflage. Nervenheilkunde 2003; 22: 531–670..
• 2 Russell D. Chronic paroxysmal hemicrania: severity, duration and time of occurrence of attacks. Cephalalgia 1984; 04: 53-6.
• 3 Pareja JA, Shen JM, Kruszewski P, Caballero V, Pamo M, Sjaastad O. SUNCT syndrome: duration, frequency, and temporal distribution of attacks. Headache 1996; 36: 161-5.
• 4 Fanciullacci M, Pietrini U, Marabini S, Boccuni M, Sicuteri F. Asymmetric mydriatic response to topical tyramine in cluster headache relatives. Int J Clin Pharmacol Res 1984; 04: 247-52.
• 5 May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352: 275-8.
• 6 Sprenger T, Boecker H, Tolle TR, Bussone G, May A, Leone M. Specific hypothalamic activation during a spontaneous cluster headache attack. Neurology 2004; 62: 516-7.
• 7 May A, Ashburner J, Buchel C. et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 1999; 05: 836-8.
• 8 Sprenger T, Valet M, Platzer S, Pfaffenrath V, Steude U, Tolle TR. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113: 422-6.
• 9 Sprenger T, Valet M, Hammes M. et al. Hypothalamic activation in trigeminal autonomic cephalgia: functional imaging of an atypical case. Cephalalgia 2004; 24: 753-7.
• 10 Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 2001; 345: 1428-9.
• 11 Leone M. Preliminary results and follow up of stereotactic electrode implant in posterior hypothalamic gray matter to relieve intractable chronic cluster headache. Neurology 2002; 58: 89-90.
• 12 Leone M, Franzini A, Broggi G, May A, Bussone G. Long-term follow-up of bilateral hypothalamic stimulation for intractable cluster headache. Brain 2004; 127: 2259-64.
• 13 Leone M, Franzini A, D’Andrea G, Broggi G, Casucci G, Bussone G. Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol 2005; 57: 924-7.
• 14 Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981; 21: 1-4.
• 15 Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. N Engl J Med 1991; 325: 322-6.
• 16 van Vliet JA, Bahra A, Martin V. et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60: 630-3.
• 17 Rozen TD. Olanzapine as an abortive agent for cluster headache. Headache 2001; 41: 813-6.
• 18 Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. Ann Neurol 2004; 56: 488-94.
• 19 Costa A, Pucci E, Antonaci F. et al. The effect of intranasal cocaine and lidocaine on nitroglycerin-induced attacks in cluster headache. Cephalalgia 2000; 20: 85-91.
• 20 Jonsdottir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache 1987; 27: 364-9.
• 21 El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 2002; 22: 205-8.
• 22 Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002; 102: 92-4.
• 23 Leone M, D’Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16: 494-6.
• 24 Pareja JA, Cuadrado ML. SUNCT syndrome: an update. Expert Opin Pharmacother 2005; 06: 591-9.
• 25 Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004; 24: 985-92.
• 26 Klapper JA, Klapper A, Voss T. The misdiagnosis of cluster headache: a non-clinic, population-based, internet survey. Headache 2000; 40: 730-5.
• 27 van Vliet JA, Eekers PJ, Haan J, Ferrari MD. Features involved in the diagnostic delay of cluster headache. J Neurol Neurosurg Psychiatry 2003; 74: 1123-5.
• 28 Torelli P, Beghi E, Manzoni GC. Validation of a questionnaire for the detection of cluster headache. Headache 2005; 45: 644-52.